<DOC>
	<DOCNO>NCT01908465</DOCNO>
	<brief_summary>Purpose : To evaluate efficiency Irritable Bowel Syndrome ( IBS ) patient treatment H1-receptor antagonist ebastine . Design : Double blind randomized placebo control trial . IBS patient receive 12-weeks treatment ebastine 20mg daily placebo ( 1:1 randomization ) .</brief_summary>
	<brief_title>Peripheral Histamine 1 Receptor Blockade IBS : Multicenter Trial</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Ebastine</mesh_term>
	<criteria>Irritable Bowel Syndrome ( IBS ) ( ROME III criterion ) : subtype diarrhea mixed form age 1865 year IBS subtype constipation medication : antidepressant H1receptor antagonists pregnancy , breast feeding comorbidity : severe kidney and/or liver disease gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>